Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Travere Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -7.4%. For fiscal 2026 it was -5.2%, against -137.9% the year before. The highest annual figure on record is 117.4% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | -5.2% | +132.7 |
| FY2025 | Dec 31, 2024 | -137.9% | −61.2 |
| FY2024 | Dec 31, 2023 | -76.7% | +177.7 |
| FY2023 | Dec 31, 2022 | -254.4% | −117.8 |
| FY2022 | Dec 31, 2021 | -136.6% | −51.2 |
| FY2021 | Dec 31, 2020 | -85.4% | −1.9 |
| FY2020 | Dec 31, 2019 | -83.5% | −21.0 |
| FY2019 | Dec 31, 2018 | -62.5% | −24.0 |
| FY2018 | Dec 31, 2017 | -38.6% | −2.7 |
| FY2017 | Dec 31, 2016 | -35.9% | −153.2 |
| FY2016 | Dec 31, 2015 | 117.4% | +510.7 |
| FY2015 | Dec 31, 2014 | -393.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | -20.5% | −9.4 |
| Q1 FY2027 | Mar 31, 2026 | -29.2% | +21.3 |
| Q4 FY2026 | Dec 31, 2025 | 2.1% | +82.7 |
| Q3 FY2026 | Sep 30, 2025 | 15.6% | +102.7 |
| Q2 FY2026 | Jun 30, 2025 | -11.1% | +119.0 |
| Q1 FY2026 | Mar 31, 2025 | -50.4% | +278.4 |
| Q4 FY2025 | Dec 31, 2024 | -80.6% | +119.5 |
| Q3 FY2025 | Sep 30, 2024 | -87.1% | −493.5 |
| Q2 FY2025 | Jun 30, 2024 | -130.1% | +135.9 |
| Q1 FY2025 | Mar 31, 2024 | -328.9% | −49.4 |
| Q4 FY2024 | Dec 31, 2023 | -200.1% | +24.2 |
| Q3 FY2024 | Sep 30, 2023 | 406.3% | +654.5 |
| Q2 FY2024 | Jun 30, 2023 | -266.0% | −31.9 |
| Q1 FY2024 | Mar 31, 2023 | -279.5% | +45.0 |
| Q4 FY2023 | Dec 31, 2022 | -224.4% | −134.3 |
| Q3 FY2023 | Sep 30, 2022 | -248.1% | −195.9 |
| Q2 FY2023 | Jun 30, 2022 | -234.1% | −162.7 |
| Q1 FY2023 | Mar 31, 2022 | -324.5% | −210.9 |
| Q4 FY2022 | Dec 31, 2021 | -90.1% | +148.5 |
| Q3 FY2022 | Sep 30, 2021 | -52.2% | −8.2 |
| Q2 FY2022 | Jun 30, 2021 | -71.4% | −17.6 |
| Q1 FY2022 | Mar 31, 2021 | -113.6% | −115.3 |
| Q4 FY2021 | Dec 31, 2020 | -238.6% | −173.7 |
| Q3 FY2021 | Sep 30, 2020 | -44.1% | +38.1 |
| Q2 FY2021 | Jun 30, 2020 | -53.8% | +32.7 |
| Q1 FY2021 | Mar 31, 2020 | 1.7% | +105.2 |
| Q4 FY2020 | Dec 31, 2019 | -64.8% | −47.8 |
| Q3 FY2020 | Sep 30, 2019 | -82.2% | +51.7 |
| Q2 FY2020 | Jun 30, 2019 | -86.6% | −32.5 |
| Q1 FY2020 | Mar 31, 2019 | -103.6% | −55.7 |
| Q4 FY2019 | Dec 31, 2018 | -17.0% | +24.7 |
| Q3 FY2019 | Sep 30, 2018 | -133.9% | −89.8 |
| Q2 FY2019 | Jun 30, 2018 | -54.0% | −19.9 |
| Q1 FY2019 | Mar 31, 2018 | -47.8% | −14.8 |
| Q4 FY2018 | Dec 31, 2017 | -41.8% | −18.7 |
| Q3 FY2018 | Sep 30, 2017 | -44.1% | +65.2 |
| Q2 FY2018 | Jun 30, 2017 | -34.1% | – |
| Q1 FY2018 | Mar 31, 2017 | -33.0% | – |
| Q4 FY2017 | Dec 31, 2016 | -23.0% | – |
| Q3 FY2017 | Sep 30, 2016 | -109.3% | – |
See a number that looks wrong?